Malignant mixed mullerian tumours of gynaecological origin: Chemosensitive but aggressive tumours

Clinical Oncology

Volumn 10, Issue 4, 1998, Pages 246-249

  Krishnan, E ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Carcinosarcoma; Case series; Chemotherapy; Gynaecological; Mesodermal; Mixed mullerian tumours; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; MIXED MULLERIAN TUMOR; OVARY TUMOR; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; UTERUS TUMOR;

EID: 0031663631     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(98)80010-1     Document Type: Article

References (23)

1. Prendiville J, Murphy D, Renninson J, et al. Carcinosarcoma of the ovary treated over a ten year period at the Christie Hospital. Int J Gynaecol Cancer 1994;4:200-5.
2. Dehner LP, Norris HJ, Taylor HB. Carcinosarcomas and mixed mesodermal tumours of the ovary. Cancer 1971;27:207-16.
3. International Federation of Gynaecology and Obstetrics. Annual Report on the results of treatment in gynaecologic cancer. Int J Gynaecol Oncol 1989,29:189-90.
4. Omura GA, Major FJ, Blessing JA, et al. A randomised study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32.
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am J Stat Assoc 1958;53:457-81.
6. Rose PG, Piver MS, Tsukada Y, et al. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer 1989;63:9358.
7. Chen SS. Propensity of retroperitoneal lymph node metastasis in patients with Stage I sarcoma of the uterus. Gynecol Oncol. 1989;32:215-7.
8. Ali S, Wells M. Mixed mullerian tumours of the uterine corpus: a review. Int J Gynaecol Cancer. 1993;3:1-11.
9. Massaet MA, Waxman M, Fruchter RG, et. al. Prognostic factors in malignant mesodermal (mullerian) tumours of the uterus. Int J Gynecol Pathol 1990;9:129-36.
10. Barakat RR, Rubin SC, Wong G, et al. Mixed mesodermal tumour of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol 1992;80:660-4.
11. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mullerian tumours of ovary and uterus. Arch Pathol Lab Med 1990;14:317-28.
12. Plaxe SC, Dottino PR, Goodman HM, et al. Clinical features of advanced mixed mesodermal tumours and treatment with doxorubicin and cisplatin based chemotherapy. Gynecol Oncol 1990;37:244-9.
13. Slayton RE, Blessing JA, DiSia PJ, et al. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 1987;71:661-2.
14. Sutton GP, Blessing JA, Rosenshein N, et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumours of the uterus. Am J Obstet Gynecol 1989;161:309-12.
15. Gershenson DM, Kavanagh JJ, Copeland LJ, et al. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 1987;5:618-21.
16. Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as a first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962-6.
17. Thigpen JT, Blessing JA, Orr JW, et al. Phase II trial of cisplatin in patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 1986;70:271-4.
18. Currie JL, Blessing JA, McGehee R, et al. Phase II trial of hydroxyurea, dacarbazine (DTIC) and etoposide (VP16) in mixed mesodermal tumours of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;61:94-6.
19. Cass I, Resnik E, Chambers JT, et al. Combination chemotherapy with etoposide, cisplatin and doxorubicin in mixed mullerian tumours of the adnexa. Gynecol Oncol 1996;61:309-14.
20. Chang J, Sharpe JC, A'Hern RP, et al. Carcinosarcoma of the ovary: incidence, prognosis treatment and survival of patients. Ann Oncol 1995;6:755-8.
21. Bicher A, Levenback C, Silva EG, et al. Ovarian malignant mixed mullerian tumours treated with platinum based chemotherapy. Obstet Gynecol 1995;85:735-9.
22. Patsner B, Greenberg S. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for ovarian mixed mullerian sarcoma: report of four cases. Gynecol Oncol 1995;58:386-8.
23. Resnik E, Chambers SK, Carcanigu ML, et al. A Phase II study of etoposide, cisplatin and doxorubicin chemotherapy in mixed mullerian tumours of the uterus. Gynecol Oncol 1995;56:370-5.